FDA Greenlights Groundbreaking Treatment for Alexander Disease

In a significant advancement for neurological health, Ionis Pharmaceuticals has secured FDA approval for Zanvastro, the first-ever disease-modifying therapy for Alexander disease, a rare and severe neurological disorder.

The approval follows a pivotal clinical trial demonstrating that patients receiving Zanvastro maintained their walking speed, a critical indicator of motor function, while those in the control group experienced a 33% decline. This finding underscores the drug's potential to stabilize motor function in affected individuals.

Moreover, the study indicated promising results for younger patients, suggesting that treatment could not only stabilize but also enhance motor function. Safety assessments revealed that serious adverse events were more frequent among participants who did not receive the treatment, highlighting the drug's favorable safety profile.

Source: www.statnews.com